A jury found STMicroelectronics infringed on a Purdue patent by making and selling products for a technology related to semiconductor devices used in high-voltage power applications.
Read More
The lawsuit seeks to prevent Inari “from continuing its brazen efforts to steal Corteva’s groundbreaking, patent-protected work,” according to the complaint.
Read More
The dispute concerns technology that the university says was developed and patented by a team of professors and graduate students to address “power bugs” in mobile phone apps.
Read More
FullBeauty Brands, which has its mail-order business in Indianapolis, is facing a lawsuit from a competitor who alleges several of FullBeauty’s swimsuits infringe on the competitor’s patented designs.
The company cut off sales right before the Christmas holiday and, in a motion filed Tuesday, Apple said it would suffer “irreparable harm” if previous court orders remain.
The decision represents a rare case of a judge overturning a jury verdict and is a major win for Lilly, which argued strenuously that its Emgality drug is substantially different than Anjovy, a drug sold by competitor Teva Pharmaceuticals.
Eli Lilly’s blockbuster drug for osteoporosis, Forteo, could face generic competition from Indian drugmaker Sun Pharmaceuticals if the company can get a federal judge to declare that a Lilly patent won’t be infringed.
Indiana University ranked 53rd among universities for patents for invention last year, a jump in the rankings from previous years.
The case involved more than 200 administrative patent judges who make up the Patent Trial and Appeal Board and issue hundreds of decisions every year. The case is of particular importance to patent holders and inventors, including major technology companies.
Indiana intellectual property attorneys had first-hand experience with the increase of patent filings during the pandemic, as researchers and inventors harnessed their creative skills while quarantining.
More and more of the work done by university researchers is being spun off into companies and commercial applications that they or the universities own or are a part of.
At issue in the five-year legal dispute was whether Dr. Rick Sasso was properly compensated for various inventions, and whether Minnesota-based Medtronic paid him sufficient royalties as spelled out in their agreements.
Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drugmaker Actavis over Lilly's Alimta cancer treatment.
Patent owners have seen massive erosion of their rights coupled with a rise in basic enforcement costs and risks.
The justices ruled unanimously Monday that patent infringement lawsuits can be filed only in states where defendants are incorporated. The case was sparked by an appeal from Carmel-based TC Heartland LLC.
The justices Monday heard arguments in a case involving Carmel-based flavoring maker TC Heartland that could end the reign of the Eastern District of Texas, which handles more than a third of all patent suits in the United States.
A unanimous Supreme Court on Tuesday sided with smartphone maker Samsung in its high-profile patent dispute with Apple over the design of the iPhone.
A center that helps Indiana University researchers commercialize their discoveries has moved its operations to be closer to faculty, industry and research partners.
Indianapolis-based Interactive Intelligence Inc. has filed a federal patent lawsuit against Avaya Inc., a competitor with which Interactive Intelligence also had a long-standing patent license agreement.
A professor in the Indiana School of Medicine is hopeful that an antibiotic cocktail he invented will one day improve the lives of millions of people, thanks in part to the Indiana University Research and Technology Corp., formed in 1997 to make work done by IU faculty and researchers available for commercial development.
A subsidiary of Zimmer Biomet Inc. in Warsaw will argue that it should not have to pay about $248 million in a patent infringement case.
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
The award is actually less than a third of what Warsaw-based Zimmer was originally ordered to pay for infringing patents on a lavage device.
